- Home
- BW vs CHRS Comparison
BW vs CHRS Comparison
Compare BW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BW
- CHRS
- Stock Information
- Founded
- BW 1867
- CHRS 2010
- Country
- BW United States
- CHRS United States
- Employees
- BW N/A
- CHRS N/A
- Industry
- BW Building Products
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BW Industrials
- CHRS Health Care
- Exchange
- BW Nasdaq
- CHRS Nasdaq
- Market Cap
- BW 95.7M
- CHRS 84.2M
- IPO Year
- BW N/A
- CHRS 2014
- Fundamental
- Price
- BW $0.97
- CHRS $0.76
- Analyst Decision
- BW Buy
- CHRS Buy
- Analyst Count
- BW 2
- CHRS 3
- Target Price
- BW $3.50
- CHRS $4.68
- AVG Volume (30 Days)
- BW 3.8M
- CHRS 1.3M
- Earning Date
- BW 08-07-2025
- CHRS 08-07-2025
- Dividend Yield
- BW N/A
- CHRS N/A
- EPS Growth
- BW N/A
- CHRS N/A
- EPS
- BW N/A
- CHRS N/A
- Revenue
- BW $734,239,000.00
- CHRS $272,251,000.00
- Revenue This Year
- BW $5.81
- CHRS N/A
- Revenue Next Year
- BW $9.24
- CHRS $106.56
- P/E Ratio
- BW N/A
- CHRS N/A
- Revenue Growth
- BW 12.90
- CHRS 19.87
- 52 Week Low
- BW $0.22
- CHRS $0.66
- 52 Week High
- BW $2.99
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BW 51.04
- CHRS 46.35
- Support Level
- BW $0.93
- CHRS $0.72
- Resistance Level
- BW $1.10
- CHRS $0.77
- Average True Range (ATR)
- BW 0.10
- CHRS 0.04
- MACD
- BW -0.03
- CHRS 0.00
- Stochastic Oscillator
- BW 7.78
- CHRS 38.69
About BW Babcock & Wilcox Enterprises Inc.
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.